IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v483y2012i7391d10.1038_nature10937.html
   My bibliography  Save this article

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Author

Listed:
  • Zhao Chen

    (Harvard Medical School
    Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Katherine Cheng

    (Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Zandra Walton

    (Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Yuchuan Wang

    (Lurie Family Imaging Center, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Brigham and Women’s Hospital)

  • Hiromichi Ebi

    (Harvard Medical School
    Massachusetts General Hospital Cancer Center)

  • Takeshi Shimamura

    (Oncology Institute, Loyola University Chicago Stritch School of Medicine)

  • Yan Liu

    (Harvard Medical School
    Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Tanya Tupper

    (Lurie Family Imaging Center, Dana-Farber Cancer Institute)

  • Jing Ouyang

    (Dana-Farber Cancer Institute)

  • Jie Li

    (Center for Survey Statistics & Methodology, Iowa State University)

  • Peng Gao

    (Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Michele S. Woo

    (Dana-Farber Cancer Institute)

  • Chunxiao Xu

    (Harvard Medical School
    Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Masahiko Yanagita

    (Dana-Farber Cancer Institute)

  • Abigail Altabef

    (Dana-Farber Cancer Institute)

  • Shumei Wang

    (Brigham and Women’s Hospital)

  • Charles Lee

    (Brigham and Women’s Hospital)

  • Yuji Nakada

    (UT Southwestern Medical Center)

  • Christopher G. Peña

    (UT Southwestern Medical Center)

  • Yanping Sun

    (Lurie Family Imaging Center, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Yoko Franchetti

    (Dana-Farber Cancer Institute, Harvard School of Public Health)

  • Catherine Yao

    (Dana-Farber Cancer Institute)

  • Amy Saur

    (Lurie Family Imaging Center, Dana-Farber Cancer Institute)

  • Michael D. Cameron

    (Translational Research Institute, The Scripps Research Institute)

  • Mizuki Nishino

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital)

  • D. Neil Hayes

    (The Lineberger Comprehensive Cancer Center, University of North Carolina)

  • Matthew D. Wilkerson

    (The Lineberger Comprehensive Cancer Center, University of North Carolina)

  • Patrick J. Roberts

    (The Lineberger Comprehensive Cancer Center, University of North Carolina)

  • Carrie B. Lee

    (The Lineberger Comprehensive Cancer Center, University of North Carolina)

  • Nabeel Bardeesy

    (Massachusetts General Hospital Cancer Center)

  • Mohit Butaney

    (Dana-Farber Cancer Institute)

  • Lucian R. Chirieac

    (Brigham and Women’s Hospital)

  • Daniel B. Costa

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • David Jackman

    (Dana-Farber Cancer Institute)

  • Norman E. Sharpless

    (The Lineberger Comprehensive Cancer Center, University of North Carolina)

  • Diego H. Castrillon

    (UT Southwestern Medical Center)

  • George D. Demetri

    (Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute)

  • Pasi A. Jänne

    (Harvard Medical School
    Dana-Farber Cancer Institute
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute)

  • Pier Paolo Pandolfi

    (Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Lewis C. Cantley

    (Harvard Medical School
    Beth Israel Deaconess Medical Center)

  • Andrew L. Kung

    (Lurie Family Imaging Center, Dana-Farber Cancer Institute
    Dana Farber Cancer Institute and Children’s Hospital)

  • Jeffrey A. Engelman

    (Harvard Medical School
    Massachusetts General Hospital Cancer Center)

  • Kwok-Kin Wong

    (Harvard Medical School
    Dana-Farber Cancer Institute
    Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute)

Abstract

In parallel with an ongoing human clinical trial, genetically engineered mouse models of lung cancer with different genetic alterations are treated with chemotherapeutic agents; the results have implications for the clinical trial.

Suggested Citation

  • Zhao Chen & Katherine Cheng & Zandra Walton & Yuchuan Wang & Hiromichi Ebi & Takeshi Shimamura & Yan Liu & Tanya Tupper & Jing Ouyang & Jie Li & Peng Gao & Michele S. Woo & Chunxiao Xu & Masahiko Yana, 2012. "A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response," Nature, Nature, vol. 483(7391), pages 613-617, March.
    • Handle: RePEc:nat:nature:v:483:y:2012:i:7391:d:10.1038_nature10937
    DOI: 10.1038/nature10937
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature10937
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature10937?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Xue Bai & Ze-Qin Guo & Yan-Pei Zhang & Zhen-zhen Fan & Li-Juan Liu & Li Liu & Li-Li Long & Si-Cong Ma & Jian Wang & Yuan Fang & Xin-Ran Tang & Yu-Jie Zeng & Xinghua Pan & De-Hua Wu & Zhong-Yi Dong, 2023. "CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:483:y:2012:i:7391:d:10.1038_nature10937. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.